Navigation Links
Lymph nodes can be key in spreading prion infectivity
Date:9/24/2007

Lymph nodes can be crucial for spreading low doses of infective prion agents -the pathogens responsible for conditions such as scrapie and Creutzfeldt-Jakob disease - into the nervous system, according to new research published in the online open access journal BMC Veterinary Research. While we can show that the regional lymph node plays no pivotal role in the neuroinvasion of prions for high doses of infection, we cannot rule out the possibility that lymph nodes are still involved in the distribution of prions throughout the body to other non-neural tissues.

The research, carried out by scientists in the group of Michael Beekes at the Robert-Koch Institute in Berlin, Germany, sheds new light on the important issue of how prion agents are transmitted from the site of infection to the brain and spinal cord, where they cause irreparable and fatal damage.

Christine Kratzel and colleagues investigated the role of the lymphoreticular system - which comprises the network of lymph nodes that is part of the body's defence system - in the spread of scrapie infection to nerve tissue in hamsters. The team discovered that if a lymph node close to the site of infection is removed within six days after a high or a medium dose of infective agent has been administered, the animal still develops the disease. However, if the node is removed 4 weeks before infection, a high dose causes the disease while a low dose does not (over the course of the 314 day time period for the study). The results suggest that for low doses of infective agent the lymphoreticular system is important in facilitating neuroinvasion i.e. the spread of prions from the infection site to the central nervous system.

The team also noted that after a node had been removed and the wound not yet healed, prion infection is substantially accelerated.

The findings are important because the role of the lymphoreticular system and inflammatory processes in the spread of prion infectivity through the body has been poorly understood. A clearer understanding of the factors involved in the transport of the agent in the body will help scientists and doctors to develop new ways of preventing and treating prion diseases.


'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

Related biology news :

1. Source of molecular triggers in cutaneous T cell lymphoma identified
2. Imaging Lymph Nodes with Nanoparticles
3. Potential Cure for Lymphoma in HIV patients
4. TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas
5. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
6. Reversal of role for a viral protein associated with the development of lymphoma
7. Tadpole soon to help in the fight against cancer and lymphedema
8. Combination therapy improves AIDS-related lymphoma outcome
9. Malaria parasites develop in lymph nodes
10. Antibiotic treats lymphoma of the eye
11. Interaction between lymph and liver cells may affect immune response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
Breaking Biology Technology: